Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Lung Cancer (Amsterdam, Netherlands)|December 24, 2014
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501Naoyuki Nogami, Nagio Takigawa, Katsuyuki Hotta, et al.
ESMO Open|July 22, 2020
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)Kyoichi Okishio, Ryo Morita, Junichi Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 16, 2019
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in JapanRyo Morita, Kyoichi Okishio, Junichi Shimizu, et al.
Cancer Science|September 14, 2020
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subsetMiyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, et al.
Cancer Science|September 20, 2021
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subsetMiyako Satouchi, Kaname Nosaki, Toshiaki Takahashi, et al.
Cancer Medicine|May 13, 2021
The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatmentNaoko Sueoka-Aragane, Chiho Nakashima, Hironori Yoshida, et al.
Cancer Science|May 15, 2023
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407Shunichi Sugawara, Kentaro Tanaka, Fumio Imamura, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2012
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.
Therapeutic Advances in Medical Oncology|March 15, 2021
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, et al.
Pageof 11